Literature DB >> 16432455

Dermatoscopic differences between atypical melanocytic naevi and thin malignant melanomas.

Tomas Fikrle1, Karel Pizinger.   

Abstract

Dermatoscopy is used to aid in the differential diagnosis of pigmented skin lesions. The aim of this study was to identify dermatoscopic differences between atypical melanocytic naevi and thin malignant melanomas. A set of 180 difficult cases (60 thin melanomas, 120 clinically atypical benign melanocytic naevi) was analysed. Differences in structure, distribution of pigmentation, presence or absence of important structures, total number of colours and asymmetry of the lesions were identified. The three-structure type, multifocal distribution of pigmentation, eccentric peripheral hyperpigmentation, multiple colours (three or more) and asymmetry of structures/colours in the dermatoscopic image were considerably more frequent in melanomas than in benign lesions (P<0.001, chi-squared test). No single dermatoscopic criterion exists to discriminate between all melanocytic lesions with sufficient confidence. Some criteria are helpful in the differential diagnosis and management of difficult cases.

Entities:  

Mesh:

Year:  2006        PMID: 16432455     DOI: 10.1097/01.cmr.0000195700.42766.23

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  3 in total

Review 1.  Using dermoscopic criteria and patient-related factors for the management of pigmented melanocytic nevi.

Authors:  Iris Zalaudek; Giovanni Docimo; Giuseppe Argenziano
Journal:  Arch Dermatol       Date:  2009-07

2.  Optical delineation of human malignant melanoma using second harmonic imaging of collagen.

Authors:  C Thrasivoulou; G Virich; T Krenacs; I Korom; D L Becker
Journal:  Biomed Opt Express       Date:  2011-04-20       Impact factor: 3.732

3.  Dermoscopic evaluation of superficial spreading melanoma.

Authors:  Fernanda Marques Trindade; Maria Luiza Pires de Freitas; Flávia Vasques Bittencourt
Journal:  An Bras Dermatol       Date:  2021-02-01       Impact factor: 1.896

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.